LENZ Therapeutics, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Evert Schimmelpennink and CFO Daniel Chevallard certified LENZ Therapeutics' Q3 2026 10-Q filing on November 3, 2026, attesting that financial statements fairly present the company's condition and results of operations, and that disclosure controls and internal controls are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine Sarbanes-Oxley certification with no exceptions or control weaknesses flagged. Standard periodic disclosure, immaterial to operations or valuation.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.